Mural Oncology PLC (NASDAQ:MURA) Receives Consensus Rating of “Hold” from Analysts

Shares of Mural Oncology PLC (NASDAQ:MURA) have received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $12.00.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mural Oncology in a report on Monday, December 8th.

Hedge Funds Weigh In On Mural Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. Shay Capital LLC acquired a new position in shares of Mural Oncology during the 3rd quarter worth $93,000. Quadrature Capital Ltd bought a new position in Mural Oncology in the second quarter valued at about $98,000. Virtu Financial LLC acquired a new position in Mural Oncology during the third quarter worth about $115,000. Rangeley Capital LLC bought a new position in shares of Mural Oncology in the second quarter worth about $115,000. Finally, BML Capital Management LLC acquired a new stake in shares of Mural Oncology in the 3rd quarter valued at approximately $119,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Stock Performance

MURA opened at $2.04 on Wednesday. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74. The firm has a market cap of $35.38 million, a P/E ratio of -0.29 and a beta of 2.93. The business’s fifty day moving average is $2.07 and its 200-day moving average is $2.18.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.38. On average, research analysts predict that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.